{"id":"NCT04362111","sponsor":"University of Alabama at Birmingham","briefTitle":"Early Treatment of Cytokine Storm Syndrome in Covid-19","officialTitle":"Early Treatment of Cytokine Storm Syndrome in Covid-19","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-01","primaryCompletion":"2021-12-31","completion":"2023-06-01","firstPosted":"2020-04-24","resultsPosted":"2023-08-24","lastUpdate":"2023-08-24"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cytokine Storm","COVID-19"],"interventions":[{"type":"DRUG","name":"Anakinra","otherNames":["recombinant human IL-ra (rhIL-1ra)"]},{"type":"DRUG","name":"Normal saline","otherNames":["NS"]}],"arms":[{"label":"Anakinra Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"PLACEBO_COMPARATOR"}],"summary":"This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.","primaryOutcome":{"measure":"Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation.","timeFrame":"Variable up to Day 28","effectByArm":[{"arm":"Anakinra Group","deltaMin":10,"sd":null},{"arm":"Control Group","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":15},"commonTop":["Anemia","Acute Renal Failure","Thrombocytopenia","Venous thrombosis","Neutropenia"]}}